Skip to content
Regulus
-
Novartis buys Regulus for US$1.7B to expand kidney disease pipeline
The acquisition centers on Regulus’ lead experimental therapy, farabursen, an oligonucleotide drug designed to target microRNA-17 in the kidneys for the treatment of autosomal dominant polycystic kidney disease (ADPKD)-a common genetic cause of renal failure worldwide.